Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2021
Company provided an update on its research and development initiatives including the FDA Phase 2 study with ketamine to treat Parkinson’s disease, treatment-resistant depression, and the development of novel microneedle patches for delivering psychedelics of it.